Ajooni Biotech Limited

As of March 31, 2025, Ajooni Biotech Limited carries a market capitalization of 964.56M, placing it among publicly traded companies globally. Its enterprise value stands at 908.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Ajooni Biotech Limited has 172.24M shares outstanding.

As of March 31, 2025, Ajooni Biotech Limited trades at a trailing price-to-earnings ratio of 25.36. The price-to-sales ratio is 0.74, and the price-to-book ratio stands at 1.10.

As of March 31, 2025, Ajooni Biotech Limited trades at an EV/EBITDA multiple of 22.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 908.52M versus a market cap of 964.56M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2025, Ajooni Biotech Limited maintains a current ratio of 11.31, meaning it holds 11.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.20, indicating elevated leverage, while an interest coverage ratio of 13.32 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2025, Ajooni Biotech Limited posted a return on equity (ROE) of 5.14, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.30 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.71, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.32, useful for judging operating efficiency across full business cycles. The company generates approximately 9.01M in revenue per employee across its workforce of 127.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.92 indicates how many times Ajooni Biotech Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2025, Ajooni Biotech Limited recorded 9.85M in income tax expense. That works out to an effective tax rate of 22.68, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 43.42M, leaving 33.59M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Ajooni Biotech Limited's stock has declined approximately 42.72% over the past 52 weeks. The 50-day moving average sits at 3.38, while the 200-day moving average is 3.97.

Over the twelve months ended March 31, 2025, Ajooni Biotech Limited generated 1.15B in revenue and converted that into 33.59M in net income, yielding earnings per share of 0.22. EBITDA reached 39.84M, while operating income came in at 29.17M.

As of March 31, 2025, Ajooni Biotech Limited holds 75.44M in cash and equivalents against 19.40M in total debt, resulting in a net debt position of -48.90M. Total book value stands at 880.79M, with working capital of 565.23M providing operational flexibility.

Over the twelve months ended March 31, 2025, Ajooni Biotech Limited posted a gross margin of 15.66, reflecting its pricing power and cost economics. The operating margin of 2.54 and net profit margin of 2.93 provide insight into operational efficiency.

Ajooni Biotech Limited's most recent stock split took place on May 7, 2024 with a 231:262 split ratio.